Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA …,

A second clinical candidate, AC0058, is a next generation BTK inhibitor, currently in a Phase 1b trial for Lupus patients in the US, which can potentially …, A second clinical candidate, AC0058, is a next generation BTK inhibitor, currently in a Phase 1b trial for Lupus patients in the US, which can potentially …, Read More

Scroll to Top